The burgeoning Indian pharma industry will be getting a booster shot with PharmaLytica 2014. The event organised by UBM India, host of CPhI / P-MEC India, will be held at BIEC, Bengaluru from September 25 to 27. PharmaLytica is the maiden edition of UBM's second pharma show in India
As about $92 billion worth patented drugs are expected to go off patent in the United States, it has given a big opportunity to the Indian pharmaceutical industry where generics account for approximately 75 per cent of the total sales. The Indian pharma market is the world's third-largest in terms of volume and13 th largest in terms of value. The industry size is expected to increase from $24.87 billion in 2013 to $47.88 billion by 2018 at a CAGR.of14 per cent.
Thus, the Indian pharma companies have the opportunity to capitalise on the patent cliff and gain a greater share of the growing generic market. Currently, India accounts for nearly 40 per cent of generic drugs and over-the-counter products and 10 per cent of finished dosages used in the US. During 2014-2016; about US$92 billion worth patented drugs are expected to go off patent in the US as compared with US$65 billion during 2010-12. Indian companies share in the US generic market has growth rapidly on the back of aggressive ANDA filings and successful pursuit of Para-IV, capitalising on the patent expiries of blockbuster drugs.
According to a CARE Ratings report, the drug patent expiry in the US will create new opportunity for Indian pharmaceutical industry in the coming years and the pharma industry will gain a larger foothold in the world's generic market. In the long term, semi-regulated markets like Latin America, Africa and Asia may offer the next growth avenues for Indian pharma companies as these markets have high demand for drugs and relatively less stringent regulatory compliance resulting in lower cost of servicing these markets.
This growth would be primarily driven by factors like increasing sales of generic medicines, a greater penetration in rural markets and heightened health awareness. Other factors are increasing affluence, changing lifestyles resulting in higher incidence of lifestyle-related diseases, increasing government expenditure on healthcare such as Central Government Health Scheme (CGHS), National Programme for Healthcare of the Elderly (NPHCE), Rashtiya Arogya Nidhi (RAN) and Janani Surakasha Yojna (JSY). The industry is highly fragmented with more than 20,000 registered manufacturing units, of which approximately 250 large units that constitute about 70 per cent of the total domestic market value.
Further the CARE report, has pointed out that Indian pharma companies secured 39 per cent of total 400 ANDA approvals from US FDA as against 37 per cent of total 476 ANDA approvals during 2012. Thus, generic manufacturers are leveraging this opportunity by increasing their ANDA filings. Further, low-cost manufacturing base and around 523 US FDA drug manufacturing facilities as at the end of March 2013 will able to tap future opportunity. Rising M&A activities and US Healthcare Insurance reforms will also play positive role in future growth.
Biopharma companies are also aiming to capture 10 per cent of the global market for biosimilars by 2020 which will enable India to become one of the top five producers in the world.
PharmaLytica 2014 is thus taking place at a time Indian pharma industry is taking giant strides on the global arena. Along with the exhibition and conference, the event will see a congregation of R&D heads and decision makers from pharmaceuticals, contract research, clinical trials and biotechnology. Serving as an industry platform, the event will connect the pharmaceutical expertise from Karnataka with pharmaceutical manufacturers, outsourcing solution providers, including clinical trials, contract research, custom manufacturing, biotech, IT and analytical services from across India and select global markets.
According to CARE report, domestic consumption accounted for about 47 per cent and export market about 53 per cent of the total production in India in FY'13. The domestic market has grown at a CAGR of about 11 per cent in the past five years ended FY13 on the back of increase in lifestyle-related diseases, rising penetration of medical insurance, healthcare infrastructure development, increase in per capita income, etc. On the other hand, export market has grown at a higher CAGR of about 19 per cent in the past five years ending FY13 due to increase demand for generics on the back of patent expiries of several high-value drugs such as Lipitor (Pfizer), Boniva (Roche), Combivir (GlaxoSmithKline), etc.
India exports pharmaceutical products to more than 200 nations and the US is the largest export market among all countries; being the world's largest generic drug market. Exports to the US are primarily driven by increased ANDAs approvals by US FDA and Indian pharma companies ability to produce high-quality medicines at competitive prices.
According to the commerce ministry data, the country's pharma exports aggregated US$ 10.1 billion during FY13 as against US$ 8.48 billion during FY12. Exports to US accounted for approximately 31 per cent of the total pharmaceutical product export by India during FY13. During first nine months of FY14, the country's pharma exports aggregated to US$ 8.04 billion, out of which USA accounted for 31 per cent. PharmaLytica integrates UBM's expertise and understanding of pharmaceuticals, bioservices, analytical & lab services with the limitless possibilities on the pharma industries and presents it as one solid B2B package.
The event will see participation of over 100 exhibitors including industry leaders like Aditya Birla Group of Science & Technology, Thermax, Newtronic Lifecare Equipment, Borosil Glass Works, Thermolab Scientific Equipments, Millipore India Pvt, KNF Pumps + Systems (India), Peak Scientific Instrument (India), Clearsynth Labs Ltd, Integrated Cleanroom Technologies and Eureka Forbes Ltd amongst others.
The event is supported by Karnataka Drugs and Pharmaceuticals Manufacturers’ Association (KDPMA). PharmaLytica has also received support from India Pharmaceutical Association (IPA), Confederation of Indian Pharmaceutical Industry (CiPi) and Association of Contract Research Organization (ACRO).
Says Joji George, Managing Director, UBM India “PharmaLytica 2014 will form a backdrop for all the key players in the Indian pharmaceutical sector congregate to connect, share and ideate. Against the Indian landscape for the pharma industry, with Karnataka leading the biotechnology revolution and attracting large investments in the sector, UBM India opted for the state capital to host PharmaLytica 2014. The choice of city as a venue for the event has been further validated by the fact that the state has over 180 biotech companies in India, amongst which, over 130 companies are based in Bengaluru.”
Commenting on the event, Jatish Sheth, President, KDPMA said, “UBM India and KDPMA are working closely to bring in participation of industry players at the inaugural event of PharmaLytica 2014. Through this industry event, we look forward to showcase Karnataka and South Region of India as a upcoming pharma hub with great potential to build business opportunities within India as well as globally, thus making Karnataka, the preferred global destination for the pharma sector.”
PharmaLytica is the combination of a trade fair and conference where participants can pick up on the latest industry trends, techniques and methods. It is a platform connecting the pharmaceutical community with outsourcing solution providers, including clinical trials, contract research, custom manufacturing, biotech, IT and analytical services.
PharmaLytica 2014 will be spread over 2,000 sqm. featuring over 100 plus exhibitors. The event will help to develop contacts with existing clients and potential future business partners; showcase products and services to the global pharmaceutical industry and stay ahead of competition and keep up with the latest news/trends/innovations.
Conferences at PharmaLytica offers a chance to learn about pharmaceutical, biotechnology, analytical services, contract research industries and more.
Exhibition and conference facilities at BIEC are first of its kind in India which offer services and amenities of the highest quality at par with international standards. This complex, created with only one purpose - to make it a preferred destination for international business exhibitions, trade fairs, congresses, international conferences, seminars and training programmes in India.
This multi-purpose 34 acres beautifully landscaped complex has 40,000 sqm of covered column-less air-conditioned exhibition space (three exhibition halls), a multi-facility conference centre spread over 5,600 sqm including four conference halls, a helipad, an Amphitheatre, VIP lounge, food court of 7500 sqm, a machine tool training centre,and large outdoor area. It also has an infrastructure to distribute 11 MW of power supply.